ArticleTranslational cancer research2026
Network pharmacology approach and experimental verification of Danzhi Xiaoyao Powder for breast cancer treatment based on UHPLC-Q-Orbitrap HRMS.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Danzhi Xiaoyao Powder (DZXYP), a classical formulation in traditional Chinese medicine (TCM), exhibits promising effects in suppressing the proliferation and migration of breast cancer (BC) cells; nonetheless, its detailed pharmacological mechanisms have not yet been fully elucidated. This study sought to explore the mechanism by which DZXYP targets the PI3K/AKT/mTOR signaling pathway to treat BC through serum pharmacology, network pharmacology, and Methods: Serum samples from Sprague-Dawley rats orally administered DZXYP were analyzed using ultra-high-performance liquid chromatography-quadrupole orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) to identify contained compounds. Results: The current investigation integrated molecular docking (MD), network pharmacology, metabolomics analysis, and Conclusions: This study aimed to elucidate the mechanism of DZXYP in treating BC through network pharmacology and experimental validation. The findings demonstrated that 46 active components of DZXYP and 26 key targets are primarily associated with steroid and lipid metabolism, which regulate malignant BC progression through the PI3K/AKT and mTOR pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.